Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the hiv drugs market grown in recent years?

The market size for HIV drugs has experienced consistent growth over recent years. An increase from $34.91 billion in 2024 to $36.41 billion in 2025, reflecting a compound annual growth rate (CAGR) of 4.3%, is anticipated. Factors such as expanded governmental support and policies, escalated spending on healthcare and HIV R&D, growth in reported HIV cases, heightened awareness, and economic progress in developing markets have contributed to the growth during the historic period.

How is the hiv drugs market size expected to evolve during the forecast period?

The market size for healthcare workforce management systems is projected to experience significant expansion in the coming years. By 2029, this market is projected to escalate to a value of $4.12 billion, growing at a compound annual growth rate (CAGR) of 14.8%. This projected growth within the forecast period can be credited to factors such as the rise of telehealth, prioritisation of work-life balance, an increase in interoperability requirements, emphasis on continual learning, emergence of healthcare consumerism, and the adaptation of value-based payment methods. Key trends poised to shape the forecast period encompass the incorporation of cloud-based workforce management solutions, adoption of patient-focused staffing models, mobile workforce solutions, utilisation of predictive analytics in workforce planning, and a shift towards data-oriented decision-making processes.

Get your hiv drugs market report here!

https://www.thebusinessresearchcompany.com/report/hiv-drug-global-market-report

Which key drivers are propelling the hiv drugs market’s growth?

The uptick in awareness amongst people concerning the identification and treatment of HIV is a significant factor propelling the growth of the HIV drug market. Detecting and dealing with HIV/AIDS, a highly chronic disease, is garnering extensive awareness due to the disease’s worldwide prevalence. For instance, the United States-based humanitarian organization, UNICEF, reported in July 2024 that an estimated 40.0 million individuals were living with HIV globally in 2023. Of this figure, 2.38 million were children between 0 to 19 years old. In the year 2023, around 685 children contracted HIV each day and about 250 kids succumb to their AIDS diagnosis daily. Therefore, the amplified awareness and understanding of HIV’s diagnosis and treatment act as crucial propellers for the expansion of the HIV drug market.

What are the market segments in the hiv drugs industry?

The HIV drugs market covered in this report is segmented –

1) By Type: Nucleoside Reverse Transcriptase Inhibitors (NRT’s), Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s), Protease Inhibitors, Integrase strand transfer inhibitors (INSTIs), Other Types

2) By Administration: Oral, Parenteral

3) By Application: Hospital Pharmacies, Retail Pharmacies, Other Applications

Subsegments:

1) By Nucleoside Reverse Transcriptase Inhibitors (NRTIs): Zidovudine (AZT), Lamivudine (3TC), Abacavir (ABC), Tenofovir disoproxil fumarate (TDF), Other NRTIs

2) By Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): Efavirenz (EFV), Nevirapine (NVP), Etravirine (ETR), Rilpivirine (RPV), Other NNRTIs

3) By Protease Inhibitors (PIs): Ritonavir (RTV), Lopinavir (LPV), Darunavir (DRV), Atazanavir (ATV), Other PIs

4) By Integrase Strand Transfer Inhibitors (INSTIs): Raltegravir (RAL), Dolutegravir (DTG), Bictegravir (BIC), Other INSTIs

5) By Other Types: Entry Inhibitors, Fusion Inhibitors, Combination Therapies

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2834&type=smp

Which leading companies are shaping the growth of the hiv drugs market?

Major companies operating in the HIV drugs market include Gilead Sciences Inc., Johnson & Johnson, Merck & Co. Inc., Boehringer Ingelheim International GmbH, Cipla, Aurobindo Pharma, AbbVie, Emcure Pharmaceuticals, Micro Labs Limited, Northeast Pharmaceutical Group Co. Ltd, Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd, Strides Arcolab Limited, Hetero Labs Limited, Shanghai Desano Bio-pharmaceutical Co., Anhui Biochem Biopharmaceutical Co. Ltd., China’s National Health Commission (NHC), Shanghai Xinxing Medicine Co. Ltd., China Meheco Xinxing Pharma Co. Ltd., CytoDyn Inc., Janssen Pharmaceutical, Bavarian Nordic, Roche Laboratories, Pharmstandard, Pharmasyntez, R-Pharm, Alium, ChemRar Group, Gritstone Oncology, Enzolytics Inc., BioClonetics Immunotherapeutics Inc., Dewpoint Therapeutics, Lyndra Therapeutics, Mylan N.V., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Teva Canada, ViiV Healthcare Canada, GSK, Abbott Laboratories, Aspen Pharmacare Limited, Pharmacare Ltd.

What key trends are currently impacting the hiv drugs market’s development?

Key players in the HIV drugs market are entering into strategic alliances for the production of Lenacapavir, in an effort to speed up its development, widen its accessibility, and boost their global market footprint. Lenacapavir, a novel HIV-1 capsid inhibitor, shows significant effectiveness when used in conjunction with other antiretrovirals and attacks various stages of the HIV lifecycle, making it a potential alternative for patients with limited treatment options. For example, in August 2023, Dr. Reddy’s Laboratories and Hetero, both pharmaceutical companies based in India, joined forces with Gilead Sciences Inc, a US-based biopharmaceutical firm. The goal of this collaboration is to produce and distribute the HIV drug lenacapavir across 120 primarily low- and lower-middle-income countries (LMICs). This move is especially advantageous for patients with multi-drug-resistant HIV who have undergone extensive treatments, thus expanding the availability of this innovative medicine.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2834

Which geographic areas are influencing the growth of the hiv drugs market?

North America was the largest region in the HIV drugs market share in 2024. Middle East is expected to be the largest growing region in the global HIV drug market during the forecast period. The regions covered in the HIV drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Drugs for Immunotherapy Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/drugs-for-immunotherapy-global-market-report

Cellular Immunotherapy Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

Hormonal Contraceptives Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/hormonal-contraceptives-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: